邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对中重度银屑病患者血清脂肪因子水平的影响:前瞻性非随机对照试验

乔菊,  李峰,  何春霞,  吴超,  晋红中

downloadPDF
文章导航 > 协和医学杂志  > 2019 >  10(3): 243-248
乔菊, 李峰, 何春霞, 吴超, 晋红中. 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对中重度银屑病患者血清脂肪因子水平的影响:前瞻性非随机对照试验[J]. 协和医学杂志, 2019, 10(3): 243-248. doi: 10.3969/j.issn.1674-9081.2019.03.010
引用本文: 乔菊, 李峰, 何春霞, 吴超, 晋红中. 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对中重度银屑病患者血清脂肪因子水平的影响:前瞻性非随机对照试验[J]. 协和医学杂志, 2019, 10(3): 243-248. doi: 10.3969/j.issn.1674-9081.2019.03.010
shu
Ju QIAO, Feng LI, Chun-xia HE, Chao WU, Hong-zhong JIN. Effects of the Receptor-IgG Fc Fusion Protein of Recombinant Type Ⅱ Human Tumor Necrosis Factor-α on the Levels of Serum Adipokines in Psoriatic Patients: A Prospective Non-randomized Controlled Trial[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 243-248. doi: 10.3969/j.issn.1674-9081.2019.03.010
Citation: Ju QIAO, Feng LI, Chun-xia HE, Chao WU, Hong-zhong JIN. Effects of the Receptor-IgG Fc Fusion Protein of Recombinant Type Ⅱ Human Tumor Necrosis Factor-α on the Levels of Serum Adipokines in Psoriatic Patients: A Prospective Non-randomized Controlled Trial[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 243-248. doi: 10.3969/j.issn.1674-9081.2019.03.010
shu

重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对中重度银屑病患者血清脂肪因子水平的影响:前瞻性非随机对照试验

doi: 10.3969/j.issn.1674-9081.2019.03.010

  • 中国医学科学院 北京协和医学院 北京协和医院皮肤科, 北京 100730

基金项目: 

中国医学科学院医学与健康科技创新工程服务"一带一路"战略先导科技专项 2017-I2M-B&R-01

详细信息
    通讯作者:

    晋红中 电话:010-69151500, E-mail:jinhongzhong@263.net

  • 中图分类号: R751.05

Effects of the Receptor-IgG Fc Fusion Protein of Recombinant Type Ⅱ Human Tumor Necrosis Factor-α on the Levels of Serum Adipokines in Psoriatic Patients: A Prospective Non-randomized Controlled Trial

  • Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要:   目的  分析注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对中重度斑块型银屑病患者血清脂联素(adiponectin, APN)、视黄醇结合蛋白4(retinol binding protein 4, RBP4)、瘦素(leptin, LEP)3种脂肪因子水平的影响。  方法  选取2016年11月至2018年5月在北京协和医院皮肤科就诊的30例中重度斑块型银屑病患者作为治疗组, 同时选取在本院健康医学部进行体检的25名健康人作为健康对照组。治疗组均给予重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白50 mg皮下注射, 每周1次, 共12次。检测健康对照组及治疗组治疗前(基线)和治疗后12周血清APN、RBP4、LEP的浓度; 分析两组之间以及治疗组治疗前后血清脂肪因子水平是否存在差异, 并采用Spearman相关分析法评估治疗组基线血清APN、RBP4、LEP表达水平与银屑病皮损面积和严重程度指数(psoriasis area and severity index, PASI)之间有无线性相关关系。  结果  治疗组基线APN水平[9.73(6.69, 12.37)比(14.25(10.53, 23.28), P＜0.001]、LEP水平[0.42(0.17, 2.60)比3.90(1.38, 7.20), P=0.002]较健康对照组降低, RBP4较健康对照组升高[12.29(10.62, 21.33)比9.13(7.36, 15.78), P=0.024];治疗组治疗后APN水平[11.95(8.12, 15.26)比9.73(6.69, 12.37), P=0.027]、LEP水平[2.84(1.04, 9.34)比0.42(0.17, 2.60), P＜0.001]较治疗前明显升高, 而RBP4水平较治疗前差异无统计学意义(P=0.125);基线APN、RBP4、LEP浓度均与PASI无线性相关关系。  结论  脂肪因子可能参与了银屑病的慢性炎症过程, 抗肿瘤坏死因子α治疗可能改善银屑病的炎症状态。
    Abstract:   Objective  To analyze the effects of the receptor-IgG Fc fusion protein of recombinant type Ⅱ human tumor necrosis factor-α(TNF-α) on serum levels of adiponectin (APN), retinol binding protein 4(RBP4), and leptin (LEP) in patients with moderate to severe plaque psoriasis.  Methods  A total of 30patients with moderate to severe plaque psoriasis and 25 healthy volunteers were enrolled in the study. The psoriatic patients were subcutaneously injected with type Ⅱ human TNF-α receptor-IgG Fc fusion protein 50 mg once a week for 12 weeks. The serum levels of APN, RBP4, and LEP were assessed and compared before and after the treatment of 12 weeks, in psoriatic patients, as well as in the controls. Spearman correlation analysis was used to evaluate the linear correlations of baseline serum APN, RBP4, LEP levels with psoriasis area and severity index(PASI) in the treatment group.  Results  Before the treatment, the levels of APN[9.73(6.69, 12.37) vs. 14.25(10.53, 23.28), P < 0.001] and LEP[0.42(0.17, 2.60) vs. 3.90(1.38, 7.20), P=0.002] were lower, RBP4 was higher[12.29(10.62, 21.33) vs. 9.13(7.36, 15.78), P=0.024] in psoriatic patients than those in normal controls. After the treatment, the levels of APN[11.95(8.12, 15.26)vs. 9.73(6.69, 12.37), P=0.027] and LEP[2.84(1.04, 9.34)vs. 0.42(0.17, 2.60), P < 0.001] in the psoriatic patients were markedly increased, while the level of RBP4 showed no significant change(P=0.125). There was no linear correlation of the levels of APN, RBP4, LEP with PASI in the baseline period.  Conclusions  APN, RBP4 and LEP are closely related to the chronic inflammatory state of psoriasis. Anti-TNF-α therapy may improve the metabolic state of patients with psoriasis.
    利益冲突  无
    • HTML全文

  • 图  1  30例中重度银屑病患者基线期血清APN(A)、RBP4(B)、LEP(C)水平与PASI的相关性

    APN、RBP4、LEP：同表 2；PASI：银屑病皮损面积和严重程度指数

    下载: 全尺寸图片 幻灯片

    表  1  治疗组与健康对照组一般资料比较

    组别 性别
    (男/女, n)    		 年龄
    [M(Q), 岁]    		 BMI
    (x±s, kg/m2)
    治疗组(n=30) 19/11 36(29, 46) 23.87±1.67
    健康对照组(n=25) 16/9 36(27, 48) 24.17±2.46
    χ2/Z/t值 0.003 6.242 0.54
    P值 0.959 0.793 0.592
    BMI：体质量指数
    下载: 导出CSV

    表  2  治疗前治疗组与健康对照组血清脂肪因子水平比较 [M(Q)]

    组别 APN(μg/ml) RBP4(μg/ml) LEP(ng/ml)
    治疗组(n=30) 9.73(6.69, 12.37) 12.29(10.62, 21.33) 0.42(0.17, 2.60)
    健康对照组(n=25) 14.25(10.53, 23.28) 9.13(7.36, 15.78) 3.90(1.38, 7.20)
    Z值 -3.753 -2.265 -3.026
    P值 ＜0.001 0.024 0.002
    APN：脂联素；RBP4：视黄醇结合蛋白4；LEP：瘦素
    下载: 导出CSV

    表  3  30例中重度银屑病患者治疗前后血清脂肪因子水平比较 [M(Q)]

    组别 APN(μg/ml) RBP4(μg/ml) LEP(ng/ml)
    治疗前 9.73(6.69, 12.37) 12.29(10.62, 21.33) 0.42(0.17, 2.60)
    治疗12周后 11.95(8.12, 15.26) 11.81(9.14, 14.88) 2.84(1.04, 9.34)
    Z值 -2.211 -1.532 -4.227
    P值 0.027 0.125 ＜0.001
    APN、RBP4、LEP：同表 2
    下载: 导出CSV
    • 参考文献(22)
  • [1] 余晓玲, 吴超, 晋红中.银屑病、心血管疾病与脂肪因子[J].中国医学科学院学报, 2018, 40:556-562. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgyxkxyxb201804019
    [2] Coumbe AG, Pritzker MR, Duprez DA, et al.Cardiova scular risk and psoriasis:beyond the traditional risk factors[J].Am J Med, 2014, 127:12-18.
    [3] Chiricozzi A, Raimondo A, Lembo S, et al.Crosstalk between skin inflammation and adipose tissue-derived products:pathogenic evidence linking psoriasis to increased adiposity[J].Expert Rev Clin Immunol, 2016, 12:1299-1308. doi:  10.1080/1744666X.2016.1201423
    [4] Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases:potential mechanistic links between skin disease and co-morbid conditions[J]. J Invest Dermatol, 2010, 130:1785-1796. doi:  10.1038/jid.2010.103
    [5] Moschen AR, Wieser V, Tilg H. Adiponectin:key player in the adipose tissue-liver crosstalk[J]. Curr Med Chem, 2012, 19:5467-5473. https://pubmed.ncbi.nlm.nih.gov/22876924/
    [6] Eder L, Jayakar J, Pollock R, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity[J]. Ann Rheum Dis, 2013, 72:1956-1961. doi:  10.1136/annrheumdis-2012-202325
    [7] Li RC, Krishnamoorthy P, DerOhannessian S, et al. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors[J]. Clin Exp Dermatol, 2014, 39:19-24. doi:  10.1111/ced.12250
    [8] Shibata S, Tada Y, Hau C, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis:induction of elevated serum adiponectin levels following therapy[J]. Br J Dermatol, 2011, 164:667-670. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM21062267
    [9] Kaur S, Zilmer K, Leping V, et al. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis[J]. J Eur Acad Dermatol Venereol, 2011, 25:1328-1333. doi:  10.1111/j.1468-3083.2011.03982.x
    [10] Gerdes S, Osadtschy S, Rostami-Yazdi M, et al. Leptin, adiponectin, visfatin and retinol-binding protein-4-mediators of comorbidities in patients with psoriasis?[J].Exp Dermatol, 2012, 21:43-47. doi:  10.1111/j.1600-0625.2011.01402.x
    [11] Ozdemir M, Yüksel M, Gökbel H, et al. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporine[J]. J Dermatol, 2012, 39:443-448. https://pubmed.ncbi.nlm.nih.gov/22300284/
    [12] Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes[J]. Nature, 2005, 436:356-362. doi:  10.1038/nature03711
    [13] Romani J, Caixàs A, Ceperuelo-Mallafré V, et al. Circula-ting levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI[J]. Arch Dermatol Res, 2013, 305:105-112。 doi:  10.1007/s00403-012-1306-5
    [14] Karadag AS, Ertugrul DT, Kalkan G, et al. The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris:a noncontrolled study[J]. Dermatology, 2013, 227:103-108. doi:  10.1159/000351769
    [15] Moraes-Vieira PM, Yore MM, Dwyer PM, et al. activates antigen presenting cells, leading to adipose tissue inflammation and systemic insulin resistance[J]. Cell Metab, 2014, 19:512-526. doi:  10.1016/j.cmet.2014.01.018
    [16] Erikstrup C, Mortensen OH, Nielsen AR, et al. RBP-to-retinol ratio, but not total RBP, is elevated in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2009, 11:204-212. doi:  10.1111/j.1463-1326.2008.00901.x
    [17] Abella V, Scotece M, Conde J, et al. Leptin in the interplay of inflammation, metabolism and immune system disorders[J]. Nat Rev Rheumatol, 2017, 13:100-109. doi:  10.1038/nrrheum.2016.209
    [18] Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis:leptin and resistin as mediators of cutaneous inflammation[J]. Br J Dermatol, 2008, 159:342-350. doi:  10.1111/j.1365-2133.2008.08655.x
    [19] Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis[J]. Exp Dermatol, 2011, 20:81-87. doi:  10.1111/j.1600-0625.2010.01210.x
    [20] Wang Y, Chen J, Zhao Y, et al. Psoriasis is associated with increased levels of serum leptin[J]. Br J Dermatol, 2008, 158:1134-1135. doi:  10.1111/j.1365-2133.2008.08456.x
    [21] Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis[J]. Br J Dermatol, 2008, 159:1207-1208. https://pubmed.ncbi.nlm.nih.gov/18795929/
    [22] Cerman AA, Bozkurt S, Sav A, et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis[J]. Br J Dermatol, 2008, 159:820-826. doi:  10.1111/j.1365-2133.2008.08742.x
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
图(1) / 表(3)
计量
  • 文章访问数:  243
  • HTML全文浏览量:  38
  • PDF下载量:  7
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-01-23
  • 刊出日期:  2020-09-18

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！